General Information of This Drug (ID: DMOHK1E)

Drug Name
Docosanol   DMOHK1E
Synonyms
Abreva; Debat; Doconsanol; Erazaban; Healip; Herepair; Lidakol; Lidavol; Tadenan; Behenic alcohol; Behenyl alcohol; Docosanol [USAN]; Docosyl alcohol; IK 2; Lanette 22; NAA 422; Stenol 1822; Stenol 1822A; Abreva (TN); Docosanol (USAN); Docosanol (VAN); Erazaban (TN); IK.2; N-Docosanol; Nacol 22-97; V-1326;BEHENYL ALCOHOL, 98%; Docosan-1-ol; Behenyl alcohol, Abreva, 1-Docosanol, Docosanol; Behenyl alcohol, AI3-36489, Behenic alcohol, 1-Docosanol, Docosyl alcohol, IK-2, Tadenan; 1-DOCOSANOL
Indication
Disease Entry ICD 11 Status REF
Herpes simplex virus infection 1F00 Approved [1]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Docosanol + Idarubicin DCKMGJS Idarubicin Glioblastoma? (Cell Line: T98G) [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020941.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.